This course gives an overview of the pharmacovigilance activities and the related documents throughout the life cycle of a medicinal product. Key terminology and concepts will be presented, with a focus on benefit-risk analysis.

Pharmacovigilance Documents – Basic Concepts and Definitions for Pharmacovigilance Writing

“A never ending story (life cycle management in pharmacovigilance)”

  • The life cycle of a medicinal product from the pharmacovigilance perspective
  • Basic concepts and definitions for pharmacovigilance writing
  • Benefit-risk analysis
  • Breakout sessions and interactive discussion of the results
  • Interaction of the main pharmacovigilance documents through the life cycle of medicinal products.
  • Assessment and review of key concepts

Professionals involved in the planning, preparation, coordination and review of aggregated safety reports.
In particular:
Drug Safety and Pharmacovigilance department, Regulatory Affairs department and Quality and Compliance department (e.g. medical writers, pharmacovigilance writers, pharmaco­vigilance officers, pharmacovigilance managers, QPPVs, safety physicians, managers regulatory affairs and medical evaluators/advisors, document quality and compliance managers).

Participant experience
Basic knowledge of drug development and pharmacovigilance.

Presentation, hands-on exercises, group, and class discussions with a limited number of attendees.

Marco Anelli

Marco Anelli

Medical Affairs and Pharmacovigilance consultant

Marco has a medical degree from the University of Milan, specializations in Medical Statistics and Clinical Pharmacology from the University of Pavia and an international master’s degree in health economics and pharmacoeconomics from the University of Pompeu Fabra in Barcelona, plus formal training in Data Science and Artificial Intelligence.
In the last few years, he has extensively worked in the fields of pharmacoeconomics and health technology assessment.
Marco has been a free-lance consultant in Medical Affairs and Pharmacovigilance/ Drug Safety since 2022.

Before that, he has been “Head of Pharmacovigilance and Medical Affairs Advisory Services” at ProductLife Group (PLG).
As “Deputy Chief Scientific Officer”, always at PLG, Marco has also coordinated all delivery and research projects (internal and on behalf of clients) linked to Big Data, Knowledge Management, Artificial Intelligence and Machine Learning.
Previously, Marco was R&D Director at Keypharma, an Italy-based consultancy company (later acquired by PLG), where was responsible for the oversight of all clinical and preclinical aspects of projects run internally and on behalf of clients.
Drawing on a career in the pharmaceutical industry that spans more than 30 years, Marco provides expert oversight on a wide range of R&D and Medical Affairs related activities.
Marco has participated in and supervised all stages of drug development – from formulation to Phase I-IV and pharmacovigilance.
In addition, Marco is a qualified QPPV and has prepared and overseen more than 200 non-clinical and clinical overviews and summaries.
Before joining Keypharma and PLG, Marco was Medical Affairs Director at Eurand.

Tiziana von Bruchhausen

Tiziana von Bruchhausen

Principal Pharmacovigilance Writer at Boehringer Ingelheim

Tiziana von Bruchhausen, PhD specialises in pharmacovigilance writing and has gained over 10 years’ experience while working in various roles for mid-sized and large pharmaceutical companies. She is currently employed as a principal pharmacovigilance writer at Boehringer Ingelheim. Her tasks and responsibilities cover pre- and post-submission activities related to the global strategic planning and the preparation of pharmacovigilance documents with a focus on DSURs, RMPs, PSURs, and health authorities’ assessment reports.
Tiziana actively promotes the professional role of medical writers in pharmacovigilance through workshops and lectures Europe-wide and has served as a session chair at international conferences. She is an active volunteer at the European Medical Writers Association (EMWA), where she has been chairing since 2017 the Pharmacovigilance Special Interest Group Committee. She was Vice President of EMWA in 2017-2018 and President in 2018-2019.

Online training in 1 module 

13 September 2023 – h.09:00 am / 01:00 pm CEST

The training course admits maximum 12 attendees.

The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.


This course is part of the training path “Pharmacovigilance Documents in the Life Cycle of a Medicinal Product”. Click here for the path details 


Early Bird: € 495,00 * (until 23 August 2023)

Ordinary: € 625,00*

Freelance – Academy – Public Administration**: € 375,00*

* for Italian companies: +22% VAT

** Early Bird discount not applicable to Freelance – Academy – Public Administration fee

The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.


Ticket non più acquistabile

Versione Stampabile
Cosa saprai fare dopo il corso
Risultato atteso
describe basic concepts and terms needed in pharmacovigilance and will have a good overview of the benefit-risk analysis
Risultato atteso
understand and describe the main pharmacovigilance activities in the life cycle of the medicinal product and the interrelation among DSUR, PSUR/PBRER, RMP, and AddCO.

<p>Online interactive training on Zoom platform.</p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform.

LS Academy will provide the access link to the virtual platform a few days before the training.

<p>Online interactive training on Zoom platform.</p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>